Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Cytokinetics, Incorporated

Biotech Giants' Cost Trends: Regeneron vs. Cytokinetics

__timestampCytokinetics, IncorporatedRegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 201444426000205018000
Thursday, January 1, 201546398000392709000
Friday, January 1, 201659897000299694000
Sunday, January 1, 201790296000397061000
Monday, January 1, 201889135000434100000
Tuesday, January 1, 201986125000782200000
Wednesday, January 1, 2020969510001119900000
Friday, January 1, 20211599380002437500000
Saturday, January 1, 20222408130001560400000
Sunday, January 1, 20233301230001815800000
Monday, January 1, 20241970500000
Loading chart...

Unlocking the unknown

Cost of Revenue Trends: A Tale of Two Biotech Giants

In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This chart provides a fascinating glimpse into the cost of revenue trends for Regeneron Pharmaceuticals, Inc. and Cytokinetics, Incorporated from 2014 to 2023. Over this period, Regeneron consistently outpaced Cytokinetics, with its cost of revenue peaking at approximately 1.8 billion in 2023, a staggering 780% increase from 2014. In contrast, Cytokinetics saw a more modest rise, with a 640% increase, reaching around 330 million in 2023.

Regeneron's significant growth in cost of revenue reflects its expanding operations and increased production capabilities, likely driven by its successful product pipeline. Meanwhile, Cytokinetics' steady rise indicates a strategic focus on research and development. This data underscores the contrasting strategies of these two biotech leaders, offering valuable insights for those looking to invest in the future of healthcare innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025